You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Mallinckrodt
Medtronic
Moodys
Dow

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 10,106,605

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,106,605
Title:Compositions and methods for antibodies targeting Epo
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
Inventor(s): Ghosh; Joy (Brookline, MA), Rutz; Mark Anthony (Munich, DE), Tissot-Daguette; Kathrin Ulrike (Neuried, DE), Splawski; Igor (Cambridge, MA), Roguska; Michael (Cambridge, MA)
Assignee: NOVARTIS AG (Basel, CH)
Application Number:15/180,879
Patent Claims:see list of patent claims

Details for Patent 10,106,605

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial NOVARTIS AG (Basel, CH) 2032-12-05 RX search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial NOVARTIS AG (Basel, CH) 2032-12-05 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial NOVARTIS AG (Basel, CH) 2032-12-05 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial NOVARTIS AG (Basel, CH) 2032-12-05 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,106,605

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Moodys
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.